Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPP-PERINATAL pooled retrospective analysis of fetal ultrasound and prognosis in perinatal/infantile hypophosphatasia
jRCT1050220128Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of asfotase alfa in hypophosphatasia (HPP) and infantile hypophosphatasia (HPP), sponsored by AstraZeneca. Primary endpoints: Association between fetal ultrasound findings and postnatal motor development by HPP disease type, Association between fetal ultrasound findings and postnatal respiratory status by HPP disease type and 2 more. Started Dec 2022; status: active, not recruiting.
02
Drugs
asfotase alfa
03
Conditions
hypophosphatasia (HPP)infantile hypophosphatasia (HPP)
Beyond the preview
Go deeper on jRCT1050220128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1050220128.